Is there any possibility that selenium and homocysteine play a role in metastatic ability of colorectal tumors?

Basit Öğe Kaydı
dc.authorwosidHakan, Mehmet Tolgahan / AAW-8118-2020
dc.authorwosidYAYLIM, ILHAN / AAA-9573-2021
dc.contributor.authorHorozoglu, Cem
dc.contributor.authorRajab, Basem Mabruk M.
dc.contributor.authorTuran, Saime
dc.contributor.authorErbasoglu, Oncu Koc
dc.contributor.authorKucukhuseyin, Ozlem
dc.contributor.authorHakan, Mehmet Tolgahan
dc.contributor.authorYaylim, Ilhan
dc.date.accessioned2021-11-01T15:05:16Z
dc.date.available2021-11-01T15:05:16Z
dc.date.issued2020
dc.department[Belirlenecek]
dc.description.abstractIntroduction: The data suggesting that metabolites and genes of homocysteine may play a role in the pathogenesis of colorectal cancer are available in the literature. Similarly, selenium (Se) levels and SELENBP1, a member of the selenoprotein family characterized by selenium, have been evaluated for the etiopathology of colorectal cancer (CRC). In this study, we aimed to determine the levels of homocysteine (Hcy), Se, and SELENBP1 gene expression in tumor tissue according to histopathological stages in patients with CRC. Materials and methods: Hcy levels were determined by ELISA, and Se levels were determined by atomic absorption from serum samples isolated from peripheral blood of 56 colorectal cancer cases and 87 healthy controls. The expression of SELENBP1 gene in tumor samples was determined by RT-PCR method. The histopathological evaluations of the patients were evaluated according to the AJCC-8th staging system. Results: Se levels were 67.56 +/- 3.11 ng/mL in colorectal cancer patients and 61.92 +/- 21.26 ng/mL in control group patients (p = 0.078). Serum Hcy levels were 11.34 +/- 1.75 ng/mL in the patient group and 20.87 +/- 4.38 in the control group (p = 0.340). The SELENBP1 fold change was found to be 3.78 +/- 1.95-fold higher in tumor tissues compared to internal control (p = 0.755). Se levels were found to be 1.23 times lower in patients with distant metastasis than in patients without distant metastasis (p = 0.029). Similarly, Hcy level was found to be 1.79 times lower in patients with metastasis than in non-metastatic patients (p = 0.035). Conclusion: Our data suggest that low Se and Hcy levels may play an important role in the histopathological aspects of metastatic ability and CRC.
dc.description.sponsorshipIstanbul University Scientific Research Project UnitIstanbul University [TYO-2019-33675]en_US
dc.description.sponsorshipThis study was supported by Istanbul University Scientific Research Project Unit (Project No: TYO-2019-33675).en_US
dc.identifier.doi10.5414/TEX01610
dc.identifier.endpage62en_US
dc.identifier.issn0946-2104
dc.identifier.issue2en_US
dc.identifier.startpage55en_US
dc.identifier.urihttps://doi.org/10.5414/TEX01610
dc.identifier.urihttps://hdl.handle.net/11491/7200
dc.identifier.volume37en_US
dc.identifier.wosWOS:000539395900002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherDustri-Verlag Dr Karl Feistle
dc.relation.ispartofTrace Elements And Electrolytes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjecthomocysteine (Hcy)en_US
dc.subjectselenium (Se)en_US
dc.subjectcolorectal cancer (CRC)en_US
dc.subjectSELENBP1en_US
dc.titleIs there any possibility that selenium and homocysteine play a role in metastatic ability of colorectal tumors?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu